A Greek research team led by Giorgos Skretas has developed an innovative pharmaceutical molecule that, in preclinical tests, restored learning and memory capacity in animal models with characteristics of Alzheimer’s disease.
The discovery is the result of collaboration between scientists at the Alexander Fleming Biomedical Sciences Research Centre, the National Hellenic Research Foundation and the spin-off company ResQ Biotech. The molecule, RSQ-020, acts by targeting the Tau protein which, when it folds abnormally and forms aggregates, is linked to the onset and progression of serious neurodegenerative disorders.
